Titre : Empreinte moléculaire

Empreinte moléculaire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Functional Status
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Empreinte moléculaire : Questions médicales les plus fréquentes", "headline": "Empreinte moléculaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Empreinte moléculaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-24", "dateModified": "2025-03-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Empreinte moléculaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Techniques de chimie synthétique", "url": "https://questionsmedicales.fr/mesh/D060326", "about": { "@type": "MedicalCondition", "name": "Techniques de chimie synthétique", "code": { "@type": "MedicalCode", "code": "D060326", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.897.836.249" } } }, "about": { "@type": "MedicalCondition", "name": "Empreinte moléculaire", "alternateName": "Molecular Imprinting", "code": { "@type": "MedicalCode", "code": "D054802", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Zhimin Liu", "url": "https://questionsmedicales.fr/author/Zhimin%20Liu", "affiliation": { "@type": "Organization", "name": "Faculty of Science, Kunming University of Science and Technology, Kunming 650500, China. Electronic address: lab_chem@126.com." } }, { "@type": "Person", "name": "Alessandra Maria Bossi", "url": "https://questionsmedicales.fr/author/Alessandra%20Maria%20Bossi", "affiliation": { "@type": "Organization", "name": "Department of Biotechnology, University of Verona, Strada Le Grazie 15, Verona 37134, Italy." } }, { "@type": "Person", "name": "Jinhua Li", "url": "https://questionsmedicales.fr/author/Jinhua%20Li", "affiliation": { "@type": "Organization", "name": "CAS Key Laboratory of Coastal Environmental Processes and Ecological Remediation, Shandong Key Laboratory of Coastal Environmental Processes, Research Center for Coastal Environmental Engineering and Technology, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China." } }, { "@type": "Person", "name": "Xian Liu", "url": "https://questionsmedicales.fr/author/Xian%20Liu", "affiliation": { "@type": "Organization", "name": "School of Urban Construction, Wuhan University of Science and Technology, Wuhan, 430065, China." } }, { "@type": "Person", "name": "Lei Zhu", "url": "https://questionsmedicales.fr/author/Lei%20Zhu", "affiliation": { "@type": "Organization", "name": "School of Urban Construction, Wuhan University of Science and Technology, Wuhan, 430065, China. 200844529@qq.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Pretransplant Functional Status Predicts Postoperative Morbidity and Mortality after Liver Transplantation in Patients with Cirrhosis.", "datePublished": "2023-02-15", "url": "https://questionsmedicales.fr/article/36789574", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5009/gnl220337" } }, { "@type": "ScholarlyArticle", "name": "Analysis of Functional Status of Genetically Diverse OipA Gene in Indian Patients with Distinct Gastrointestinal Disease.", "datePublished": "2022-12-13", "url": "https://questionsmedicales.fr/article/36512098", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00284-022-03137-4" } }, { "@type": "ScholarlyArticle", "name": "Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy.", "datePublished": "2024-08-02", "url": "https://questionsmedicales.fr/article/39095808", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12933-024-02378-w" } }, { "@type": "ScholarlyArticle", "name": "Low phase angle: A predictor of functional status and discharge disposition in acute stroke older patients.", "datePublished": "2024-03-27", "url": "https://questionsmedicales.fr/article/38777433", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clnesp.2024.03.028" } }, { "@type": "ScholarlyArticle", "name": "Data from the European registry for patients with McArdle disease (EUROMAC): functional status and social participation.", "datePublished": "2023-07-25", "url": "https://questionsmedicales.fr/article/37488619", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13023-023-02825-z" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Technologie, industrie et agriculture", "item": "https://questionsmedicales.fr/mesh/D013676" }, { "@type": "ListItem", "position": 3, "name": "Technologie", "item": "https://questionsmedicales.fr/mesh/D013672" }, { "@type": "ListItem", "position": 4, "name": "Technologie pharmaceutique", "item": "https://questionsmedicales.fr/mesh/D013678" }, { "@type": "ListItem", "position": 5, "name": "Techniques de chimie synthétique", "item": "https://questionsmedicales.fr/mesh/D060326" }, { "@type": "ListItem", "position": 6, "name": "Empreinte moléculaire", "item": "https://questionsmedicales.fr/mesh/D054802" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Empreinte moléculaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Empreinte moléculaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Empreinte moléculaire", "description": "Comment l'empreinte moléculaire est-elle utilisée en diagnostic ?\nQuels tests utilisent l'empreinte moléculaire ?\nL'empreinte moléculaire peut-elle identifier des pathogènes ?\nQuels types d'échantillons sont analysés ?\nL'empreinte moléculaire est-elle précise ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Functional+Status&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Empreinte moléculaire", "description": "Quels symptômes peuvent être détectés par empreinte moléculaire ?\nL'empreinte moléculaire peut-elle détecter des allergies ?\nPeut-on utiliser l'empreinte pour des maladies auto-immunes ?\nQuels biomarqueurs sont liés aux maladies cardiovasculaires ?\nL'empreinte moléculaire peut-elle aider au diagnostic précoce ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Functional+Status&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Empreinte moléculaire", "description": "Comment l'empreinte moléculaire aide-t-elle à la prévention des maladies ?\nPeut-on utiliser l'empreinte pour des dépistages réguliers ?\nL'empreinte moléculaire peut-elle aider à la vaccination ?\nQuels programmes de santé utilisent l'empreinte moléculaire ?\nL'empreinte moléculaire peut-elle réduire les épidémies ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Functional+Status&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Empreinte moléculaire", "description": "L'empreinte moléculaire est-elle utilisée en thérapie ?\nComment l'empreinte moléculaire aide-t-elle en pharmacologie ?\nPeut-on créer des vaccins avec l'empreinte moléculaire ?\nL'empreinte moléculaire aide-t-elle à la délivrance de médicaments ?\nQuels traitements peuvent bénéficier de l'empreinte moléculaire ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Functional+Status&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Empreinte moléculaire", "description": "Quelles complications peuvent survenir avec l'empreinte moléculaire ?\nL'empreinte moléculaire peut-elle causer des effets secondaires ?\nComment minimiser les complications liées à l'empreinte ?\nLes complications affectent-elles la fiabilité des tests ?\nQuelles sont les limites de l'empreinte moléculaire ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Functional+Status&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Empreinte moléculaire", "description": "Quels facteurs influencent l'efficacité de l'empreinte moléculaire ?\nL'âge est-il un facteur de risque pour l'empreinte moléculaire ?\nLes maladies préexistantes affectent-elles l'empreinte ?\nLe mode de vie influence-t-il les résultats de l'empreinte ?\nLes médicaments peuvent-ils interférer avec l'empreinte moléculaire ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Functional+Status&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment l'empreinte moléculaire est-elle utilisée en diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de détecter des biomolécules spécifiques dans des échantillons biologiques." } }, { "@type": "Question", "name": "Quels tests utilisent l'empreinte moléculaire ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests immunologiques et chromatographiques pour identifier des analytes spécifiques." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle identifier des pathogènes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est utilisée pour détecter des virus et bactéries dans des échantillons cliniques." } }, { "@type": "Question", "name": "Quels types d'échantillons sont analysés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Sang, urine, salive et autres fluides biologiques peuvent être analysés." } }, { "@type": "Question", "name": "L'empreinte moléculaire est-elle précise ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle offre une haute sélectivité et sensibilité pour les cibles moléculaires." } }, { "@type": "Question", "name": "Quels symptômes peuvent être détectés par empreinte moléculaire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des biomarqueurs associés à des maladies comme le cancer ou des infections." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle détecter des allergies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut identifier des allergènes spécifiques dans des échantillons." } }, { "@type": "Question", "name": "Peut-on utiliser l'empreinte pour des maladies auto-immunes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle aide à détecter des auto-anticorps dans des maladies auto-immunes." } }, { "@type": "Question", "name": "Quels biomarqueurs sont liés aux maladies cardiovasculaires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme la troponine peuvent être détectés par empreinte moléculaire." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle aider au diagnostic précoce ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle permet une détection précoce de biomarqueurs associés à des maladies." } }, { "@type": "Question", "name": "Comment l'empreinte moléculaire aide-t-elle à la prévention des maladies ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de détecter des biomarqueurs de risque, facilitant des interventions précoces." } }, { "@type": "Question", "name": "Peut-on utiliser l'empreinte pour des dépistages réguliers ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est adaptée pour des dépistages réguliers de certaines maladies." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle aider à la vaccination ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut identifier des cibles pour le développement de nouveaux vaccins." } }, { "@type": "Question", "name": "Quels programmes de santé utilisent l'empreinte moléculaire ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des programmes de dépistage du cancer et de surveillance des infections." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle réduire les épidémies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle aide à identifier rapidement les agents pathogènes lors d'épidémies." } }, { "@type": "Question", "name": "L'empreinte moléculaire est-elle utilisée en thérapie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle est principalement utilisée pour le diagnostic, mais peut guider des traitements." } }, { "@type": "Question", "name": "Comment l'empreinte moléculaire aide-t-elle en pharmacologie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de concevoir des médicaments ciblant des molécules spécifiques." } }, { "@type": "Question", "name": "Peut-on créer des vaccins avec l'empreinte moléculaire ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être utilisée pour développer des vaccins ciblant des pathogènes." } }, { "@type": "Question", "name": "L'empreinte moléculaire aide-t-elle à la délivrance de médicaments ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut améliorer la délivrance ciblée de médicaments dans l'organisme." } }, { "@type": "Question", "name": "Quels traitements peuvent bénéficier de l'empreinte moléculaire ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements pour le cancer, les infections et les maladies métaboliques." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'empreinte moléculaire ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des faux positifs ou négatifs peuvent survenir, affectant le diagnostic." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle causer des effets secondaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est une méthode d'analyse et ne cause pas d'effets secondaires directs." } }, { "@type": "Question", "name": "Comment minimiser les complications liées à l'empreinte ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "En utilisant des protocoles standardisés et en validant les méthodes de détection." } }, { "@type": "Question", "name": "Les complications affectent-elles la fiabilité des tests ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications peuvent réduire la fiabilité des résultats des tests." } }, { "@type": "Question", "name": "Quelles sont les limites de l'empreinte moléculaire ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les limites incluent la spécificité et la sensibilité, pouvant varier selon les cibles." } }, { "@type": "Question", "name": "Quels facteurs influencent l'efficacité de l'empreinte moléculaire ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "La nature de la molécule cible et les conditions de synthèse des polymères." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour l'empreinte moléculaire ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'âge peut influencer la concentration de biomarqueurs dans les échantillons." } }, { "@type": "Question", "name": "Les maladies préexistantes affectent-elles l'empreinte ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent modifier les niveaux de biomarqueurs détectés par empreinte." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il les résultats de l'empreinte ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs comme l'alimentation et l'exercice peuvent affecter les biomarqueurs." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils interférer avec l'empreinte moléculaire ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent altérer les niveaux de biomarqueurs dans les tests." } } ] } ] }

Sources (10000 au total)

Pretransplant Functional Status Predicts Postoperative Morbidity and Mortality after Liver Transplantation in Patients with Cirrhosis.

This study aimed to investigate whether pretransplant frailty can predict postoperative morbidity and mortality after liver transplantation (LT) in patients with cirrhosis.... We retrospectively reviewed 242 patients who underwent LT between 2018 and 2020 at a tertiary hospital in Korea.... Among them, 189 patients (78.1%) received LT from a living donor. Physical frailty at baseline was assessed by the Short Physical Performance Battery (SPPB), by which patients were categorized into tw... Assessment of pretransplant frailty, as measured by SPPB, provides important prognostic information for clinical outcomes in cirrhotic patients undergoing LT....

Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy.

Persons with diabetes are at risk for developing a cardiomyopathy through several pathophysiological mechanisms independent of traditional risk factors for heart failure. Among those with diabetic car... In this prespecified subgroup analysis of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF) trial, 685 participants with asymptomatic DbCM underwent ba... The median NT-proBNP was 71 (Q1, Q3: 33, 135) ng/L. No association was observed between NT-proBNP concentrations and echocardiographic parameters of either diastolic or systolic dysfunction including ... Among patients with subclinical DbCM, elevated NT-proBNP concentrations are associated with worse health status, lower activity levels, and reduced functional capacity, but not with cardiac structural... ARISE-HF, NCT04083339 Date Registered August 23, 2019....

Low phase angle: A predictor of functional status and discharge disposition in acute stroke older patients.

This study aimed to investigate the effects of low phase angle (PhA) on functional status and discharge disposition during the acute phase in older patients with acute stroke.... We included consecutive patients who experienced acute stroke between October 2021 and December 2022. The exclusion criteria included: age<65 years, admission from other than home, death during hospit... Ultimately, a total of 205 patients were included in this analysis. More patients in the low PhA group were unable to be independent (27.7% vs. 66.7%, P < 0.001) and were unable to be discharged home ... Low PhA is a risk factor for low functional status at hospital discharge; it decreases the likelihood of home discharge in older patients with acute stroke....

Data from the European registry for patients with McArdle disease (EUROMAC): functional status and social participation.

The European registry for individuals with GSD5 and other muscle glycogenosis (EUROMAC) was launched to register rare muscle glycogenosis in Europe, to facilitate recruitment for research trials and t... Following the initial report on demographics, neuromuscular features and comorbidity (2020), we here present the data on social participation, previous and current treatments (medication, supplements,... Of 282 participants with confirmed diagnoses of muscle glycogenosis, 269 had GSD5. Of them 196 (73%) completed all questionnaires; for the others, the data were incomplete. The majority, 180 (67%) wer... The EUROMAC registry have provided insight into the functional and social status of participants with GSD5: most participants are socially active despite limitations in physical and daily life activit...

Poor functional status at the time of waitlist for pediatric lung transplant is associated with worse pretransplant outcomes.

Whether functional status is associated with survival to pediatric lung transplant is unknown. We hypothesized that completely dependent functional status at waitlist registration, defined using Lansk... Retrospective cohort study of pediatric lung transplant registrants utilizing United Network for Organ Sharing's Standard Transplant Analysis and Research files (2005-2020). Primary exposure was compl... A total of 964 patients were included (63.5% ≥ 12 years, 50.2% cystic fibrosis [CF]). Median waitlist days were 95; 20.1% were removed for death/deterioration and 68.2% for transplant/improvement. Com... Pediatric lung transplant registrants with the worst functional status had worse pretransplant outcomes, especially for adolescents and CF patients. Functional status at waitlist registration may be a...

Functional status associated with postural dizziness, but not postural hypotension, in older adults: a community-based study.

Functional status, postural dizziness (PD), and postural hypotension (PH) were important issues in older adults. Only one study on the relationship for the three of them in female was without adjustin... Based on a stratified randomized cluster sampling, 1361 subjects ≥ 65 years in the community were recruited from Tainan City, Taiwan, from 2000 to 2001. PH was defined as a decrease in systolic/diasto... After adjusting other variables, ADL disability (OR: 1.84, 95% CI: 1.35-2.51) and IADL disability (OR: 1.62, 95% CI: 1.21-2.17) were associated with PD, but not PH. In male and female subgroups, ADL d... Impaired functional status, shown using ADLs or IADLs, was positively associated with PD, but not PH in older adults ≥ 65 years. Clinically, it may be important to evaluate PD in older adults with ADL...

Decline in Functional Status While on the Waiting List Predicts Worse Survival After Lung Transplantation.

To determine if decreases in the Karnofsky Performance Score (KPS) while on the waitlist predict decreased survival after lung transplantation (LTx).... A retrospective evaluation of the United Network for Organ Sharing database. The KPS was evaluated at the time of listing for transplant and at the time of transplantation. Group I consisted of patien... Retrospective observational database review.... Adult patients undergoing lung transplantation.... None. Patients were stratified according to a change in their KPS.... Patient and graft survival of patients with decreasing or not decreasing KPS were compared. Of the 27,558 subjects included in the analysis, 17,986 (65%) had worsening KPS, which was associated with w... Deterioration of KPS on the waiting list for LTx is associated with significantly greater postoperative mortality in patients after LTx. These results should be taken into consideration when allocatin...

Post-COVID: effects of physical exercise on functional status and work ability in health care personnel.

Post-COVID fatigue significantly limits recovery and return-to-work in COVID-19 survivors. We aimed to assess the effects of physical exercising on post-COVID-19-symptoms, physical/mental capacities a... Thirty-two HCWs were enrolled in two groups based on Post-COVID-Functional Scale (PCFS) scores: (1) severe (SSG,... VO... Post-COVID exercise intervention improved physical fitness, psychological outcomes and workability in HCWs. Cases with severe fatigue showed higher benefit levels compared to those with mild symptoms....

Functional status of hospitalized pediatric patients with COVID-19 in southern Brazil: a prospective cohort study.

The present study aimed to assess the functional status of children diagnosed with COVID-19 at the time of hospitalization and the associations with clinical features.... This prospective cohort study was carried out with children diagnosed with COVID-19 admitted to a tertiary hospital. The patients' functioning was assessed using the pediatric Functional Status Scale ... A total of 62 children with a median age of 3 years old were included in the study, and 70% had some comorbidity prior to the diagnosis of COVID-19. The median length of stay was nine days, during whi... We observed that more than half of the children hospitalized due to COVID-19 had some level of functional change. Greater alterations in functional status were associated with the presence of previous...